It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Potassium channels of the Two-Pore Domain (K2P) subfamily, KCNK1-KCNK18, play crucial roles in controlling the electrical activity of many different cell types and represent attractive therapeutic targets. However, the identification of highly selective small molecule drugs against these channels has been challenging due to the high degree of structural and functional conservation that exists not only between K2P channels, but across the whole K+ channel superfamily. To address the issue of selectivity, here we generate camelid antibody fragments (nanobodies) against the TREK-2 (KCNK10) K2P K+ channel and identify selective binders including several that directly modulate channel activity. X-ray crystallography and CryoEM data of these nanobodies in complex with TREK-2 also reveal insights into their mechanisms of activation and inhibition via binding to the extracellular loops and Cap domain, as well as their suitability for immunodetection. These structures facilitate design of a biparatropic inhibitory nanobody with markedly improved sensitivity. Together, these results provide important insights into TREK channel gating and provide an alternative, more selective approach to modulation of K2P channel activity via their extracellular domains.
K2P channels are important regulators of cellular electrical activity. Here the authors show how nanobody fragments can be used to detect and modulate TREK2 K2P channel activity to provide insight into the mechanism of gating.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Oxford, Clarendon Laboratory, Department of Physics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Centre for Medicines Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Oxford, Clarendon Laboratory, Department of Physics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of Oxford, Clarendon Laboratory, Department of Physics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 University of Oxford, Centre for Medicines Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of Oxford, Clarendon Laboratory, Department of Physics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 Kiel University, Institute of Physiology, Medical Faculty, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
7 University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 Vrije Universiteit Brussel, Structural Biology Brussels, Brussels, Belgium (GRID:grid.8767.e) (ISNI:0000 0001 2290 8069); VIB, VIB-VUB Center for Structural Biology, Brussels, Belgium (GRID:grid.511529.b) (ISNI:0000 0004 0611 7947)
9 The Rosalind Franklin Institute, Didcot, UK (GRID:grid.507854.b); University of Oxford, Division of Structural Biology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
10 University of Oxford, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, OXION Initiative in Ion Channels and Disease, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
11 University of Oxford, Centre for Medicines Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, OXION Initiative in Ion Channels and Disease, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
12 University of Oxford, Clarendon Laboratory, Department of Physics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, OXION Initiative in Ion Channels and Disease, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)